ESIC...C.I.G. ROAD, NEW DELHI ... Processing Fee in the form of Demand Drafts to the Service...

1

ESIC e-TENDER ENQUIRY FORM FOR RATE CONTRACT NO – 142

FOR SUPPLY OF DRUGS & DRESSINGS

e-Tender Enquiry Form – Free of cost

CONTENTS Tender Letter

Terms & Conditions with Annexure

Check List of the Documents

Drug Schedule

EMPLOYEES’ STATE INSURANCE CORPORATION

ROOM NO. 312 & 314 HQRS. OFFICE, PANCHDEEP BHAWAN

C.I.G. ROAD, NEW DELHI – 110 002

LAST DATE OF SUBMISSION OF ONLINE & MANUAL BID: 30th Jan. 2018 at 10:00 AM.

For any further clarifications/queries for e-Procurement Portal, please contact at:

Email id for Support / Helpdesk - https://esictenders.eproc.in/hlml/Support.asp

2

EMPLOYEES' STATE INSURANCE CORPORATION ESIC Hqrs, Panchdeep Bhawan, C.I.G. ROAD, NEW DELHI

e-Tender Enquiry No.U-25/12/142/2017-Med.V Dated: 22.12.2017

On behalf of the Director General, Dy. Medical Commissioner (RC) invites online e-Tender Enquiry

No. U-25/12/142/2017-Med.V for DG ESIC Rate Contract No. 142 for supply of Drugs &

Dressings, for use of ESI institutions all over India, through e-procurement portal of ESIC -

https://esictenders.eproc.in

SUMMARY OF DG-ESIC RATE CONTRACT NO. 142

I. It is proposed to enter into a Running Rate Contract with pharmaceuticals firms which fulfill

the eligibility criteria approved by ESI Corporation for supply of drugs & dressings items

enumerated in the schedule annexed. The eligibility criteria have been given in the terms and

conditions. Pharmaceutical Firms intending to participate in the rate contract should

first ensure that they fulfill all the eligibility criteria as prescribed under the terms and

conditions, otherwise the tenders will be summarily rejected.

II. The Rate Contract will be governed by the terms and conditions enclosed with this Tender

Enquiry and no modifications / alterations etc. are allowed in any case. If any modification /

alteration is proposed or any other condition advanced by the bidder, it shall be ignored and

the bid will be disqualified.

III. Bidder is therefore advised to tender rate quotations only if the terms and conditions as

prescribed by Corporation are acceptable to them in its entirety and they fulfill all the

eligibility criteria.

IV. To participate in e-tender, bidder should register at https://esictenders.eproc.in and send Bid

Processing Fee in the form of Demand Drafts to the Service Provider at the earliest to ensure

timely registration and bid submission. The bidders should complete all stages of online bid

submission through e-procurement portal of ESIC i.e. https://esictenders.eproc.in. Bidders

should not wait for the last date. They are requested to complete the process of online bid

submission well before the closing, in order to safeguard their own interest.

V. Evaluation & finalization of Rate Contract will be based on e- bid submitted by the

bidder. It is the sole responsibility of the bidder to scan and upload clear and legible

documents for the purpose of evaluation. Any deficiency in the document submitted by the

bidder shall lead to disqualification of the bidder and shall be the sole responsibility of the

bidder.

www.esic.nic.in

RC-142

https://esic.eproc.in/

https://esictenders.eproc.in/

http://www.esic.nic.in/

3

VI. A SINGLE SEALED ENVELOPE : The bidder should put a separate sealed envelope in tender box containing

1) Original Demand Draft of EMD as calculated.

2) Original Label of all quoted drugs/ dressing material.

A single sealed envelope superscribed with the e-Tender for Rate Contract No. 142 duly

completed and addressed to Dy. Medical Commissioner (R.C.) should be dropped in the

tender box kept in R.C. Cell, Room No. 312, III Floor, ESIC Hqrs. Office, Panchdeep

Bhawan, C.I.G. Road, New Delhi – 110002 on or before 10.00 A.M. on 30th Jan 2018.

Please note that the submission of Technical Bid in the single sealed envelope is in addition

to the online bids to be submitted by the bidders and for the record of the Corporation.

VII. ONLINE TECHNICAL BID: The bidder should upload all the certificates / documents for the items tendered online in

Technical Bid. The tender shall be liable to be rejected if complete

documents/certificates/annexure are not uploaded or EMD is not submitted in time

VIII. Online Technical Bid and a single sealed envelope will be opened on 30th Jan 2018 at

10:30 hrs at the Vth Floor, Committee Room, Hqrs. Office, ESI Corp., C.I.G. Road, New

Delhi – 110002 in presence of representatives of the Pharmaceutical firms having an

authority letter for representation from the firm alongwith their identity proof in support.

IX. If any representative of the Pharmaceutical firms / bidders fails to present and / or is

absent from the bid meeting, their presence will not be marked later in any circumstances.

The absence of any representatives of the Pharmaceutical firms / bidders shall be the sole

responsibility of the firm.

X. The bid meeting will be conducted by the ESIC in the manner and procedure as prescribed

and a certificate will be obtained from all the participant / representatives of the

Pharmaceutical firms / bidders attending the bid meeting w.r.t. the same.

XI. If the date of opening of tenders is declared a public holiday, the tenders shall be opened on

the next working day at the same venue and time.

XII. PRICE BID ONLINE :

The Bidder has to fill Annexure 'P' online. Online Price Bid of only those bidders who are

found technically eligible will be opened. The communication through email will be sent to the

technically eligible bidders.

NOTE:- 1) It is responsibility of bidders to check further notifications / updates/corrigendum if any on

ESIC website - www.esic.nic.in & ESIC e-Procurement portal -https://esictenders.eproc.in

2) After uploading all the documents/ certificates/ Annexure/ Affidavits etc online bidder

should check by downloading themselves to see if documents are uploaded correctly and

they are legible to read.

Dy. Medical Commissioner (RC)


4

Important Instructions for Bidders regarding Online Payment

All bidders/contractors are required to procure Class-IIIB Digital Signature Certificate (DSC)

with Both DSC Components i.e. Signing & Encryption to participate in the E-Tenders.

Bidders should get Registered at https://esictenders.eproc.in.

Bidders should add the below mentioned sites under Internet Explorer Tools Internet

Options Security Trusted Sites Sites of Internet Explorer Trusted Sites

https://esictenders.eproc.in

https://www.tpsl-india.in

https://www4.ipg-online.com

Also, Bidders need to select “Use TLS 1.1 and Use TLS 1.2” under Internet Explorer Tools

Internet Options Advanced Security.

Bidder needs to submit Bid Processing Fee charges of Rs. 2495/- (non-refundable) in favour of

M/s. C1 India Pvt. Ltd., payable at New Delhi via Online Payment Modes such as Debit Card,

Credit Card or Net Banking for participating in the Tender.

Bidders can contact our Helpdesk at https://esictenders.eproc.in/html/Support.asp


https://www.tpsl-india.in/

https://www4.ipg-online.com/

5

e-TENDER SCHEDULE

SNo. Details Dates & time

1. Period of availability of e-Tender Enquiry

document on ESIC website-

www.esic.nic.in and ESIC e-Procurement

portal- https://esictenders.eproc.in

22.12.2017 to 30.01.2018 upto 10:00 AM

2. Last date of Online bid & EMD submission

30.01.2018 upto 10:00 AM

3. Pre-bid Meeting 16th January 2018 at 11:00 AM

at Vth Floor Conference Room,

ESIC Hqrs Office, Panchdeep Bhawan,

C.I.G. Road, New Delhi – 110002.

4. Opening of Technical Bid 30th Jan 2018 at 10.30 AM

at Vth Floor Conference Room,

ESIC Hqrs Office, Panchdeep Bhawan,

C.I.G. Road,New Delhi – 110002.

5. Opening of Price Bid Will be communicated over Email to the

bidders who are found technically eligible

6. Validity of offer 180 days from the last date of submission of

e-Tender

If the date of opening of tenders is declared a public holiday, the tenders shall be opened on the next

working day at the same venue and time.

Pre-bid Meeting

The objective of the pre-bid meeting is to answer the doubts/queries related to the provision of this

e-tendering. It is requested to send Queries/doubts for Pre-bid meeting on e-mail address

[email protected] three days before the schedule date. So that solutions & clarifications can be

prepared timely.

mailto:[email protected]

6

Earnest Money Deposit

a) The bidder must submit Earnest Money Deposit (EMD) as calculated along with this tender

by means of Demand Draft in favour of ESIC FUND ACCOUNT NO 1, New Delhi.

Bank guarantee/ Cheques / FDRs will not be accepted in any case.

b) Individual EMD for each drug has been indicated in drug schedule.

c) The total amount of Earnest Money Deposit to be submitted by each firm / bidder will depend

on number of items for which the bidder is quoting the rates. The total EMD amount shall be

cumulative value of EMD amount indicated in drug schedule for the drugs for which the

bidder is quoting the rates.

d) Please fill Annexure EMD.

Example:

If EMD for Drug A shown in the Annexure is M1, EMD for Drug B is M2 and EMD for

Drug C is M3, then total EMD would be calculated as :-

SNo. Name of the Drugs Quoted

by the bidder

Total EMD to be submitted by the bidder

1. A, B & C M1+M2+M3

2. A & B M1+ M2

3. B & C M2 + M3

4. C M3

e) However in all cases, a minimum EMD of Rs. 5 Lacs would be submitted by the participating

pharmaceutical firm / bidder i.e. if the cumulative value of EMD amount indicated in

Annexure X for the drugs quoted by the bidder is less than Rs. 5 lacs, then the bidder

would have to submit the minimum EMD of Rs. 5 Lacs.

f) For the new items / molecules / drugs / chemical / formulations or where drug wise EMD is

not specified, an EMD of Rs. 5 lacs per drug should be submitted by the participating

pharmaceutical firm.

g) Participating MSE Firms are exempted from payment of Earnest Money Deposit

(EMD).

h) The validity of the Earnest Money Deposit should be 60 Days from the opening date of

the tender.

i) The EMD of the unsuccessful bidders will be refunded to them within one month after

the award of the contract.

j) In case bidder withdraws his bid within its validity or fails to deposit performance

security within the specified time after award of contract, the Earnest Money will be

forfeited and the bidder will be debarred/ de-registered for a period of five years.

k) Earnest Money Deposit (EMD) deposited earlier will not be adjusted against this tender. The

tenders submitted without earnest money deposit will be summarily rejected.

l) E.S.I. Corporation will not pay any interest on deposited EMD and would be stand credited

to the E.S.I. Corporation Account.

7

TERMS AND CONDITIONS FOR GOVERNING THE

RATE CONTRACT

1. This rate enquiry is for the purpose of executing Rate Contract for supply of Drugs &

Dressings in ESI Hospitals/Dispensaries and other medical institutions run by the ESI

Corporation and ESIS. The rates quoted and accepted by the Director General, ESI

Corporation shall be valid for the quantities that may be purchased from time to time during

the course of the contract.

2. The quotations shall remain open for acceptance for 180 days (One hundred Eighty days)

from the date of opening of tenders.

3. The Director General, Employees' State Insurance Corporation, New Delhi reserves the right

to reject any or all offers including the lowest quotation without assigning any reasons

whatsoever. The Director General, ESI Corporation, New Delhi will also have the authority to

accept bidder's offer in respect of any one or more of the items for which bidders may have

quoted and his decision in this respect shall be final.

4. The Director General, ESI Corporation reserves the rights to invite separate quotations in his

sole discretion, to effect purchases outside this contract in the event of any urgent demand

arising in a locality where no stocks are held or otherwise.

5. ESIC will be entitled to proceed against the participating pharmaceutical firm / bidder before

the court of law or otherwise to protect its rights and remedies available under law.

6. The past performance of the bidder will be taken into consideration for award of a new Rate

Contract.

7. Bidder will have to furnish documents in support of the information given in the tender.

Original documents shall be submitted for verification as and when required

8. The bids submitted by pharmaceutical firms debarred by the ESI Corporation for

participation in ESI Rate Contract will not be considered for award of Rate Contract till the

period of debarring and they need not apply.

9. In case of any attempt for cartelization by bidder with a view to hike up the prices, all bids

will be rejected and the bidders will be debarred for five years.

10. The bidder, if selected, will have to supply drugs & dressings directly to the ESIC/ESIS.

11. Validity of the Rate Contract is two years from the date of finalization of the contract, but in

case of exigencies, period can be extended.

8

12. Rates for only such items, which can be supplied immediately on demand or latest within six

weeks of the placing of supply order through out of the period of contract as indicated above,

may be quoted

13. NOC for facility regarding import license for raw materials etc., will not be given by the

ESIC/ESIS.

14. ELIGIBILITY CRITERIA:

A. Participating Pharmaceutical firm must have a valid drug manufacturing and Import license

issued by the State Drug Controller for the drug / drugs quoted in their name and must submit

an attested copy of the same. Bidders who are marketing the drug but not manufacturing

will not be considered eligible. If above terms and conditions are not fulfilled tender will be

liable for the cancellation.

B. Participating Pharmaceutical firm should submit a non-conviction certificate issued by the

State Drug Controller, to the effect that the manufacturer has not been convicted under the

Drugs and Cosmetics Act, 1940 and rules there under during the preceding three years, for

any of the drugs for which it has quoted price. Non-Conviction Certificate must have been

issued on or after 30.09.2017 from the Drug Controller of the concerned State.

C. Participating Pharmaceutical firm must have a valid Registration Certificate issued by

Directorate General of Quality Assurance (DGQA) Ministry of Defence, Govt. of India for

manufacture and supply of drugs for Defence for the drugs quoted.

Or

Participating Pharmaceutical firm must have WHO-GMP certificate i.e., Good

Manufacturing Practices (GMP)Certificate in accordance with the WHO recommendations

issued by Central / State Drug Control Authorities/ FDA for each of the drug quoted. If it is

found subsequently that the WHO-GMP certificate has not been issued in accordance

with the guidelines issued in this regard by the Drug Controller General of India

(which includes joint inspection of the manufacturing unit by central and state drug

control authorities), the certificate as well as the tender are liable to be rejected.

Or

GMP (Good Manufacturing Practice) Certificate as per the revised Schedule ‘M’ of the Drugs

& Cosmetics Rules issued by Central / State Drug Controller/ FDA for the drugs quoted .

9

D. The Participating Pharmaceutical firm must have in house testing facilities and valid Good

Laboratory Practice (GLP Certificate) as per schedule ‘L1’ of the Drugs & Cosmetics Rules

issued by Central / State Drug Controller / FDA for the quoted drugs(as applicable). However

the bidder quoting for dressing material such as gauze & bandage etc. are exempted from

submitting GLP Certificate.

E. A certificate from the State Drug Controller concerned (should not have been issued more

than a year ago) that the Participating Pharmaceutical firm has been manufacturing and

marketing the product / products for which the bidder has quoted the price, for the last three

preceding years except for new drugs..

F. The Participating Pharmaceutical firm shall submit an unconditional undertaking to supply

drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940

(as amended). The bidder shall also undertake not to supply items / drugs “not of standard”,

“Grossly sub-standard” and “Spurious and adulterated drugs” as per the guidelines issued by

the Drug Controller of India from time to time.

G. In case of newly introduced drugs, the Participating Pharmaceutical firm will submit valid

certificate from the Drug Controller General of India in support of the claim and valid Drug

license from the Licensing Authority.

H. In case of proprietary drugs, Participating Pharmaceutical firm will submits valid

certificate to this effect from the State Drug Controller/Licensing Authority else bidder’s

claim will not be considered.

I. For the drugs which are being imported, the Participating Pharmaceutical firm will submit

valid import license issued by Drug Controller General of India and valid marketing license

issued by concerned Licensing Authority.

J. For dressing material such as Gauze and bandage etc. For such items, which are marked

ISI, the bidder will be eligible if it possesses valid ISI license issued by Bureau of Indian

Standards for the last three preceding years.

K. In case of narcotics, the Participating Pharmaceutical firm will have to submit the

narcotic drug license issued by the licensing authorities.

L. For the drugs quoted in the tender enquiry, Participating Pharmaceutical firm will have to

submit the samples on demand. If bidder fails to submit the samples within the period

specified, the tender will be rejected.

10

M. Participating Pharmaceutical firm should submit an undertaking on an affidavit of Rs. 50/-

(Rupees Fifty only) stating that they will comply with all the statues &legislation regarding

manufacturing, import, sale and supply of drugs in India and in particular the following

Acts/Enactments viz., the Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules,

1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The

Indian Statistical Institute Act, 1959, The Central Excise Act, 1944.

N. The participating pharmaceutical firm should submit a guarantee bond on a affidavit of Rs.

50/- (Rupees Fifty only) duly signed by the Notary (Annexure T) as under:-

a. “The pharmaceutical firm hereby declare that the drugs/items sold to the ESIC

under this contract shall be of best quality and workmanship and shall be strictly

in accordance with the specifications and particulars contained/mentioned in the

description clauses hereof and the pharmaceutical firm/bidder hereby guarantees

that the said drugs/items would continue to conforms to their description/

specification and the provisions of law as stated in the contract and that

notwithstanding the fact that the purchaser (inspector) may have inspected

and/or approved the said drugs/items. If the same be discovered not to conform

to the description and quality aforesaid or have deteriorated, the decision of the

ESIC in that behalf will be final and conclusive. ESIC will be entitled to reject

said drugs/items or such portion thereof as may be discovered not to conform to

the said description and quality in the manner as prescribed. Such rejection of

the drugs/items will be at the seller's risk and all the provisions herein contained

relating to rejection of drugs/items etc. or such portion thereof if is rejected by

the purchaser. Nothing herein contained shall prejudice any other right of ESIC

in that behalf under this contract or otherwise”.

11

O. Company/Authorised Signatory has to submit Employer Code No. & copy of last three

contributions towards ESI in case factory is covered under ESI Act.

OR

Company /Authorised Signatory has to submit an affidavit giving address of Manufacturing

unit with a declaration that this factory / manufacturing unit is outside the implemented area /

notified area by ESI Corporation

OR

Company /Authorised Signatory has to submit a certificate from the Regional Director that

the factory is not coverable under ESI Act, in case the factory is within the notified area.

P. The list of items for which the offer is being made should be given as per the format given in

Annexure-A. All the columns of Annexure-A should be properly filled up and no column

should be left blank.

Q. Each and every page of the tender and Annexure if any should be signed by the authorised

signatory of the pharmaceutical firm. The specimen signature of the authorised signatory

should be submitted to the Corporation along with the tender.

R. Information as per the proforma enclosed (Annexure-E) should be submitted with the

tenderFurnishing of wrong information and false documents will make the bidder ineligible

and. liable to be debarred / blacklisted from participation in ESI Rate Contracts.

S. Non submission of Annexure ‘G”, not following all the terms & conditions of Tender

Enquiry, furnishing wrong information and false documents will make the bidder ineligible

and liable to be debarred / blacklisted from participation in future ESI Rate Contracts for five

years along with forfeiture of the earnest money.

T. The Bidder should submit an affidavit on Stamp Paper, stating that the drugs, which are being

quoted, are not banned under Section 26 (A) of Drugs & Cosmetics Act. Or any other

provision of law prevailing in India.

U. All the Annexure’s (A, F, P and Detail of Licences) are to be properly filled and Annexure’s

(B, C, D, E, G, T, TO and EMD) to be uploaded, otherwise tender will liable to be rejected.

12

15. Terms & Conditions for Micro & Small Enterprises (MSE) firms quoting items reserved

for exclusive procurement from them as per Govt. Circular No. 21(1)/2011-MA dated

25.04.2012 and 21(15)/2012-MA dated 24.05.2012

A. MSE Firms must have a valid registration certificate with any of the following:

District Industries Centre

Khadi& Village Industries Commission

Khadi& Village Industries Board

Coir Board

National Small Industries Corporation

Directorate of Handicraft & Handloom

Any other Body Specified by Ministry of MSME, Govt. of India.

B. Following two items are reserved in Tender Enquiry / Rate Contract for exclusive

procurement from MSE firms only:

S.NO. Item No. Item Name & Description Packing Required

1 235

HANDLOOM COTTON GAUZE - Handloom

Cotton Gauze Absorbent (ISI marked) Size

18mx60cm One Thaan

2 236

HANDLOOM COTTON BANDAGE CLOTH -

Handloom Cotton Bandage Cloth (ISI marked) size

20 m X 100 cm. One Thaan

C. In tender, for general category of item - eligible Micro and Small Enterprises quoting

price within price band of L1 + 15% shall also be allowed to supply a portion of

requirement by bringing down their price to L1 price in a situation where L1 price is from

someone other than a Micro and Small Enterprise and such Micro and Small Enterprise

shall be allowed to supply upto 20% of the total tendered value.

D. Out of 20% target of annual procurement from Micro and Small Enterprises, a sub-target

of 20% (4% out of 20%) shall be earmarked for eligible Micro and Small Enterprises

owned by Scheduled Caste or Scheduled Tribe entrepreneurs.

E. Further in event of failure of such Micro and Small Enterprises to participate in tender

process or meet tender requirements and L1 price, 4% sub-target of procurement

earmarked for Micro and Small Enterprises owned by SC/ST entrepreneurs shall be met

from other eligible MSE units.

13

16. TURNOVER CRITERIA

(a) Turnover for schedule drugs

(i) Participating Pharmaceutical firm should have annual turnover of each of the last

three preceding financial years (2014-15, 2015-16, 2016-17) equal or more than the

sum total of the amount of individual turnover of the quoted list of the drugs.

Individual Turnover for each drug has been indicated in drug Schedule.

Example :

If Drug A has X turnover, Drug B has Y turnover and Drug C has Z turnover.

SNo. Name of the Drugs Quoted Annual Turnover of the bidder for the last three

preceding years (2014-15, 2015-16 & 2016-17)

equal or more.

1. A, B & C X+Y+Z

2. A & B X+Y

3. B & C Y+Z

4. C Z

(ii) Participating pharmaceutical Firms will have to submit audited financial

statement by registered Chartered Accountant for last three preceding financial

years (i.e. 2014-15, 2015-16 and 2016-17) in support of the annual turnover.

(iii) Fifty Percent or more of the annual turnover shall be from the trading of the

drugs in open market i.e exclusive of supply to ESI/ Government Departments. A

certificate from the Chartered Accountant with reference to sale in the open market

should be submitted.

(iv)Group turnover (other than drugs and their formulations) will not be considered

for determining the eligibility and such tenders will be rejected summarily.

(v) Please fill Annexure TO.

(b) Turnover For New drugs:

Participating pharmaceutical firms submitting the quote for new item / molecule / drug /

chemical / formulation which have been invented/ produced later than finalization of

ESIC Rate Contract No. 142 but before issuance of the present tender and where drug

wise turnover is not specified, shall have minimum turnover of Rs 50 Crores for each of

the last three preceding financial years (2014-15, 2015-16, 2016-17) in addition to

turnover criteria as specified in subclause- 16a to above.

14

c) Turnover For MSE Firms

Participating MSE firms quoting any or all items reserved for exclusive procurement from

them as listed below should have a minimum annual turnover of Rs. 5 Crores (Five

Crores) for formulations in each of the last three preceding years i.e. 2014-15, 2015-16 &

2016-17 to be eligible for participation in ESI Rate Contract.

Participating MSE firms quoting for drugs other than those exclusively reserved for

them shall have to fulfill the turnover criteria as defined for non MSE vendors

specified in 16 (a)

d) Turnover for Dressing Material/Repacking items

The Participating Pharmaceutical firm submitting the tender for Dressing Material /

Repacking items, should have a minimum turnover of Rs. 5 Crores for each of the last

three preceding years i.e. 2014-15, 2015-16 & 2016-17. Group turnover other than

Dressing/Repacking material will not be considered for determining the eligibility and

such tenders will be rejected summarily.

17. Undertaking For Performance:.

The participating pharmaceutical firm / bidder shall furnish an undertaking with respect to

timely and efficient supply of the quoted drugs as per the tender in all the locations where

ESIC / ESIS Hospital and State ESI Directorates are located. For this, participating

pharmaceutical firm should have atleast one registered office & Depot in any state of the zone

as per the description below:-

Zone 1- Kerala, Karnataka, Tamil Nadu, Pudducherry

Zone 2- Maharashtra, Goa, Telangana, Andhra Pradesh.

Zone 3- Madhya Pradesh, Gujarat, Rajasthan.

Zone 4- Chattisgarh, Odisha, Jharkhand.

Zone 5- Jammu&Kashmir, Punjab, Himachal Pradesh.

Zone 6- Delhi & Haryana, Uttar Pradesh, Uttrakhand.

Zone 7- West Bengal, North East States, Sikkim.

Participating pharmaceutical firms would submit in the tender as per Annexure L the list of

the office & Depot addresses, email ID & Telephone number located in the States along with

the name of the person Incharge. Aforesaid offices official will also be responsible for

managing the supply in the stipulated time at the ESI location of the concerned Zones under

its jurisdiction and other matters, if any.

15

18. Performance Security:

m) All Successful bidders including MSE bidder will deposit the performance Security equal

to Cumulative amount of all the awarded drug(s) in the form of Bank Guarantee of

Scheduled Commercial Bank.

Individual Performance Security amount for each drug has been indicated in Drug

Schedule.

n) Director General, ESI Corporation will be at liberty to apportion any amount due and

payable by the bidder to ESIC in respect of Non supply / Non Performance/ risk purchase

by the ESIC/ against drugs of “Not of Standard Quality” or any other amount which

becomes payable by the bidder in favour of ESIC by virtue of the terms and conditions

agreed herein and recover the same from the Performance Security. No appeal shall lie

with any authority against the decision taken by him in pursuance of this clause.

o) EMD of the successful bidder can be adjusted as part of performance security.

19. MARKING/LABELLING:

Each packing shall be printed with nomenclature of the drug and shall be labelled in

accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made

there under. Packing & packaging of the each drug must comply with the procedure provided

under the Legal Metrology Act, 2009 and rules made there under.

20. PACKING:

a) Participating Pharmaceutical firms must quote for the packing specified against each item

in the schedule annexed the rate enquiry, as any other packing may not be accepted.

b) Where the size/quantity of the pack is not specified in tender enquiry, bidders may quote

for standard packs available in the market.

c) It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes,

tins, containers etc., have "For ESI supply, Not to be sold" imprinted clearly. Any

consignment without such stamping will not be considered valid and will be rejected.

d) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be

accepted under any circumstances.

e) Participating Pharmaceutical firms / bidders shall quote the net price per tablet /

capsule and per unit for ointment / syrup / injection / drop / lotion / powder / Roll/

thaan etc. or any other formulation under the tender in detail under a tabular

format Rates quoted for Strip packing will not be accepted and the same shall result

in rejection of the bid submitted by the bidder.

16

f) Supplies to be made in proper boxes.

g) Liquid orals to be supplied only in glass/ plastic bottles conforming to IP / Drugs &

Cosmetics Act.

h) Large volume parenterals to be quoted and supplied only in plastic bottles / polypacks

conforming to I.P.

i) It should be ensured that only first use packaging material of uniform size including

Bottles and vials should be used for making supplies on the basis of ESI Rate Contract.

j) All primary packing containers should be strictly conforming to the specifications

described/ mentioned in the relevant pharmacopoeia.

k) Packing should be able to prevent damage or deterioration during transit.

l) All containers i.e. bottles, tins, cartons, tubes etc., are required to be secured with pilfer-

proof seals to ensure genuineness of the products packed and the correctness of the

contents.

21. SHELF LIFE AS ON DATE:

a. For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should

not be older than one fourth(1/4) of its shelf life from the date of manufacture.

b. For Drugs having shelf life more than Two years: As on the date of delivery, Drugs

should not be older than one sixth (1/6) of its shelf life from the date of manufacture.

c. For Imported Drugs: As on the date of delivery, Drugs should have a minimum 50% of

valid shelf life from the date of manufacture.

22. TESTING OF DRUGS:

a. Approved Rate Contract Holder should submit a Test Report that particular batch of

medicines tested by the Government/ Government approved Laboratories (as per list

circulated from ESIC Hqrs/ Hospitals/ State Govt. from time to time) along with each

supply.

b. Regular and random testing of drugs will be under taken by ESI from Govt./Govt.

approved laboratories at the time of supply and at any time during the shelf life or

whenever any defect is noticed.

The Director General, ESI Corporation shall be at liberty to undertake regular and random

testing of the drugs supplied by the pharmaceutical firm/ bidder at regular interval to

maintain and ensure the quality of drugs.

c. The report of the Govt./Govt. approved laboratory shall be accepted by the

pharmaceutical firm. In case the same is disputed by the pharmaceutical firm the report of

the Appellate Laboratory only will be accepted as final. However the same should be

submitted within three months, from the date of communication of the disputed test report

17

to the pharmaceutical firm. For this, the pharmaceutical firm should approach the

concerned Drug Control Authorities for getting the drugs tested, as per procedure, from

the Appellate Laboratory.

23. QUALITY CONTROL

i) The stores offered should comply with the provisions of the Drugs and Cosmetics Act,

1940 and the Rules made there under as and Drug Price Control order.

ii) While quoting against items with ISI Mark, it should be ensured that ISI code number is

indicated on quotation and at the time of making the supplies, the pharmaceutical firm

should ensure that the items supplied has ISI Mark as well as Code Number, as is the

statutory requirement of the Bureau of Indian Standards. The attested copy of the valid ISI

Marking license issued by Bureau of Indian Standards should be enclosed alongwith the

quotation.

iii) If any drugs supplied against this Rate Contract are found to be not of standard quality

on inspection by Competent Authority, the pharmaceutical firm will be liable to replace

the entire quantity and the cost of testing will be recovered from the supplier.

(iv) The classification of defects into different categories is as per the guidelines issued by the

Drug Controller of India & action will be taken by ESIC for each category of defects, described

as under:-

A. FOR CATEGORY A DEFECT (Spurious / Adulterated Drugs)-

If any item / Batch of the item declared Not of Standard quality (NSQ) under Category

A in 142 DGESIC Rate Contract/s.

Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be

initiated by the DDO’s wherever payment had been made already.

Forfeiture of Performance Security from the respective DGESIC Rate Contract.

Debarring of the Rate Contract holder / Pharmaceutical firm from current and all future

DGESIC Rate Contract for a period of five (5) years.

Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation

(if any) to individual/ individuals arising due to consumption of item declared NSQ and in

case of any adverse reaction reported in the Hospital during administration of the drug.

B. FOR CATEGOR ‘B’ DEFECT (Grossly Substandard Drugs)

I. If single item/ Batch of item is declared NSQ under Category B in 142 DGESIC Rate

Contract/s.

Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to

be initiated by the DDO’s wherever payment had been made already.


18

Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the

said NSQ item in the currency of the Rate contract.

Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/

compensation (if any) to individual/ individuals arising due to consumption of item

declared NSQ and in case of any adverse reaction reported in the Hospital during

administration of the drugs.

II. If more than one item/ Batch of item belonging to any individual pharmaceutical

firm is declared NSQ under Category B within a year in 142 DGESIC Rate

Contract.






Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current

and all future DGESIC Rate Contracts for a period of three years.





C. FOR CATEGORY C DEFECT (Minor Defects)

I. If single item/ Batch of item is declared NSQ under Category C in 142 DGESIC

Rate Contract/s.










II. If more than one item/ Batch of item belonging to any individual pharmaceutical

firm is declared NSQ under Category C within a year in 142 DGESIC Rate

Contract.






19

Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current

and all future DGESIC Rate Contracts for a period of three years




administration of the drugs

24. Purchase Order:

a) After the quotations have been accepted by the Director General, ESI Corporation,

purchase orders will be placed by the Director Medical Delhi/MS of ESIC/ESIS

hospitals/Directors of ESI Scheme of various States as per Schedule attached, who for the

purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and

will exercise the powers of Director General, ESI Corporation in all matters connected

with the execution of supplies and/or wherever specifically provided in the terms and

conditions of the Rate Contract. The Chief Direct Demanding Officer can also designate

any of his subordinate Officer as Direct Demanding Officer (DDO) to operate this

contract. See Annexure K –DDO’s address, Telephone no. and Email.

b) Purchase orders will be placed from time to time during the currency of the contract in

which the exact quantities required on each occasion together with the date of delivery

shall be specified by the Direct Demanding Officers.

c) No guarantee can be given as to the minimum quantity which will be drawn against this

contract but the pharmaceutical firm will supply quantity as may be ordered by the Direct

Demanding Officers during the currency of the contract.

d) Purchase orders against the contract will be accepted as long as these reach the

pharmaceutical firm on or before last date of the currency of the contract. Purchase orders

received during the closing days should be complied with in due course, in accordance

with the contract, even though in some cases owing to contract having expired, supplies

are to be executed after the expiry of the last date of contract.

25. Delivery Period of the Purchase Order:-

a) DDOs will send scanned copy of the Purchase order through email followed by

Registered AD post

b) Delivery Period will be of six weeks from the date of receiving of the purchase order

sent by email and the pharmaceutical firm shall, execute the order within stipulated

time.

20

c) During transit pharmaceutical firm should maintain the recommended temperature

of the drug (wherever indicated), otherwise if on checking it is found that

temperature has not been maintained, supply against the said order is liable to be

rejected and cancelled. It will be counted as a non-supply.

d) In case of failure to supply, the Corporation reserves the right to purchase the stocks from

other sources as risk purchase, i.e. purchase from any other pharmaceutical firm or firms,

in the rate contract or from outside the contract at the discretion of the Direct Demanding

Officer concerned at a competitive rate.

e) In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including

rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the

public/open market.

26. Penalty for non supply/late supply

a) If the pharmaceutical firm fails to execute the supply order within the stipulated period of

six weeks, a penalty of two (2) per cent of the value of the order calculated at the contract

rate per week or a part of a week will be levied. The maximum penalty for late supply

shall not exceed 10% of the total value of the order/orders. A pharmaceutical firm can

seek extension of the delivery period with the prior consent of the Director Demanding

Officers, if it is not in a position to execute the order in time. Such extension is

permissible for a maximum period of 5 weeks only but penalty will be levied.That

extension of delivery period cannot be claimed as a matter of right but will be at the

discretion of concerned Officer.

b) If the items/ drugs are not supplied by the schedule date (as indicated above or by

the extended date) full or in part, the order in respect of the quantity not supplied is

liable to be cancelled at the risk and expense of pharmaceutical firm. The extra

expenditure involved in procuring supplies from elsewhere will, in that case, be

recoverable from the pharmaceutical firm, in full at discretion of Direct Demanding

Officers. The recoveries thus due will be deducted from any sum payable by the

Direct Demanding Officer or which at any time thereafter may become payable

under this contract or any other contract placed with bidder by the Direct

Demanding Officers. He will be deemed to be exercising the powers of Director

General, ESI Corporation in case any such contingency arises. Apart from risk

purchase action, the bidder's the Performance security deposit may be forfeited and

21

shall invite other penal action like debarring from participating in ESI Corporation

Rate Contract present and future for a period of not less than five years.

c) If the pharmaceutical firm fails to execute the supply order three times at any location of

ESIC / ESIS in any part of the country during the period of rate contract, it shall be

debarred for the next five years with effect from the last failure and forfeiting of

Performance Security for that drug.

27. Quoting Of Price

a. The price charged for the stores supplied under the agreement or the rate quoted by bidder

for supply of medicines to the DG-ESIC, whichever is lower, shall in no event exceed the

lowest price at which the bidder sells the stores of identical description to any other

person(s) during the said period of agreement. If at any time during the said period, the

bidder reduces the sales price of such stores or sells such stores to any other person at a

price lower than the price chargeable under the agreement, he shall forthwith notify such

reduction in sale price to the Director General, E.S.I. Corporation and Direct Demanding

Officers and the price payable under the agreement for the stores supplied after the date of

its coming in to force will be the reduced price. The approved price in Rate Contract

shall stand correspondingly reduced. The preference in the Rate contract will not be

changed till any further fresh instructions.

b. The price must be quoted F.O.R Destination per unit as shown in the schedule annexed

and should be exclusive of GST Tax but inclusive of all charges for packing and

forwarding.

c. GST Taxes, if extra, where legally leviable and intended to be claimed, should be

distinctly shown separately alongwith the price quoted. Where this is not done, no claim

of GST taxes will be admitted at any later stage and on any ground whatsoever.

d. The purchaser will not pay separately for transit insurance and the bidder will be

responsible for delivery of items covered by the supply order in good condition at the

specified destination and for this purpose freight, insurance,octroi etc., if any, will have to

be borne by the bidder.

e. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of

stores at destination, notify the pharmaceutical firm, of any loss damage to the stores, that

may have occurred during the transit.

22

28. Payment:

a. Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the

drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills

are submitted. Notwithstanding any omission or shortcoming in the supply order it is

incumbent upon the pharmaceutical firm/bidder to supply the items as per the specifications

of the relevant rate contract.

b. Any dues or payments that have arisen to the Corporation from the pharmaceutical firm for

which no specific time limit has been laid down in the terms and conditions shall be payable

by the pharmaceutical firm within such time limit as may be prescribed in the letters/orders

addressed to the pharmaceutical firms.

c. Any payments that have been demanded as per the provisions of above clause b or under any

other clause shall be payable within the time laid down. On failure to do so: -

i) The pharmaceutical firm shall be liable to be debarred for supplying items/ drugs

etc. to the Corporation for a period not exceeding five years.

ii) The pharmaceutical firm is liable to be prosecuted in court of law.

29. ARBITRATION

a. In the event of any dispute or difference arising under these conditions or any special

conditions or contract or in connection with this contract, except as to any matters the

decision on which is specially provided for by these or special conditions the same shall

be referred to a sole arbitrator duly appointed as per the provisions of The Arbitration &

Conciliation Act, 1996 (As amended in the year 2016) and the Rules made thereunder and

for the time being in-force shall apply to the arbitration proceeding under this clause.The

venue of the Arbitration will be Delhi only. The Arbitration will be conducted in English

Language. The award of the Arbitral Tribunal shall be final, conclusive and binding on

the parties to the agreement.

b. Work under the contract shall, if reasonably possible, continue during the arbitration

proceedings and no payment due to or payable by the purchaser shall be with-held, on

account of such proceedings.

23

c. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon

the pharmaceutical firm/bidder to supply the items as per the specifications of the relevant

rate contract.

30. JURISDICTION:

All the disputes relating to this tender enquiry and Rate Contract shall be subject to the

territorial jurisdiction of Courts at Delhi only.

31. RATE REVISION:

Successful bidders shall not be entitled to any rate revision for any reason except that allowed

by Government of India.

32. INSPECTION:

The Director General, ESI Corporation, reserve the right for Inspection of the pharmaceutical

firms participating in the tenders, by the officers appointed. They can carry out inspection for

assessing the quality /capacity/capability/eligibility of the pharmaceutical firm to make

supplies on the basis of ESI Rate Contract and to ensure that the provisions of the Drugs and

Cosmetic Act, 1940 and the good manufacturing practices are being followed by firm. The

decision of the Director General shall be final in this regard.

33. PHARMACOPOEIA SPECIFICATION:

IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation

quoted as per the provisions of Drug and Cosmetics Act.

34. . GENERAL INSTRUCTIONS

a. Signing of the tender:

The tender is liable to be rejected if complete information is not given therein or if the

particulars and date (if any) asked for in the schedule to the tender are not filled in.

Individual signing the tenders or other documents connected with the contract must

specify whether he signs as:-

i) A sole proprietor of the pharmaceutical firm or constituted attorney of such sole

proprietor.

24

ii) A partner of the pharmaceutical firm, if it be a partnership firm in which case he

must have authority to refer to arbitration disputes concerning the business of the

partnership/agreement or a power of attorney.

iii) Authorised Attorney of the pharmaceutical firm if it is a company.

b. Any concealment, misrepresentation on the part of the pharmaceutical firm shall warrant

strict action which may extend to cancellation of the tender or subsequent award. Such

cancellation shall be at the sole risk of the firm / individual signing the tender or

submitting any other document.

c. In case of 34( a) (ii) a copy of partnership agreement attested by a Notary Public should

be furnished unless the same has been previously furnished to the Corporation, or an

affidavit on stamped paper by all the partners admitting execution of the partnership of the

general power of attorney should be furnished.

d. In the case of partnership firms, where no authority to refer disputes concerning the

business of the partnership has been conferred on any partner, the tender and all other

related documents must be signed by each partner of the pharmaceutical firm.

e. A person signing the tender form or any documents forming part of the contract on behalf

of another shall be deemed to warrant that he has authority to sign the same and, if on

enquiry it appears that the person so signing had no authority to do so, the purchaser may

without prejudice to other civil and criminal remedy cancel the contract and hold the

signatory liable for all costs and damages.

f. The tender will be rejected if:-

i. A pharmaceutical firm submits conditional tender.

ii. "No tax" quotations are not supported by a proof.

iii. All the papers are not complete.

iv. More than one type of rates are quoted for one product.

v. Sealed envelope containing EMD and labelsr is not sealed properly.

vi. If it is not legible and cuttings/over writings are not attested by the authorised

signatory alongwith seal.

vii. The rates quoted are not found both in figures and words. The unit for which rate

is quoted should be clearly specified.

g. Each page of photocopy of various papers/certificates attached should be attested by

Notary Public General or State Government, Gazetted Officer.

h. It is mandatory for all bidders to submit the tender online through e-procurement portal

of esic-https://esic.eproc.in The terms & conditions of the present e-Tender Enquiry

25

Form for Rate Contract are binding upon the Pharmaceutical firms / Bidders. The

submissions of the online tender and the tender under sealed envelope respectively shall

construe a concluded agreement for the purpose of invocation and enforcement of the

terms & conditions of the online tender.

35. The sealed envelope containing EMD as calculated and Original Label of the quoted drugs

should be addressed to:

Dy. Medical Commissioner (R.C.) ESI Corporation, New Delhi-110002.

Such sealed cover should be delivered by the specific time and date.

A sealed cover containing EMD and original Label will be opened manually on

the specified date and time. Online Price Bid of only those bidders, who are found

technically eligible will be opened. The date and time of opening of the price bid

in respect of bidders who fulfill eligibility criteria will be intimated to such

bidders.

36. Withdrawal of tenders' along with the earnest money will be allowed before the date of

opening of tenders.

37. After opening of tenders: -

a) withdrawal of the complete tender can be allowed but in such cases, the earnest money

shall be forfeited in full;

b) no change/alteration in rate or other terms & conditions in the tender will be permitted

under any circumstances;

c) Partial withdrawal (in respect of one or more items quoted) will not be allowed under any

circumstances.

Dy. Medical Commissioner (RC)

26

Annexure A & F

Annexure A

Item Name and

Description of the

product with Brand

Name, if any Packing

Offered

Drug

License

No. and

Date of

issue

for the

product

Date of

Mfg. of

1st

batch

of the

product

S. No. in

Annexure

B/Page

No.

Was it in

past

Rate

Contract.

If yes,

R.C. No

Was the

firm

debarred

in the

past for

the item

if so,

period of

debarring

Remarks

(Put NA if

Not

Applicable)

Annexure F

Manufactured by

Marketed

by

Type of Drug License

Self mfg. / loan

license / 3rd party Remarks (Put NA if Not Applicable)

27

DETAILS OF LICENSES

For Indigenous Items`

Details of

Licenses –

quoted

Items

Minimum 1 rows entry required. Number of Rows To Add:

S.

No

.

Item

No.

Drug License Site GMP GLP No

Conviction

Proprietary Drug

Certificate

New

molecule/Drug

Certificate

Num

ber

Valid

Upto

Page

No.

Valid

Upto

Page

No.

Valid

Upto

Page

No.

Date

of

Issue

Page

No.

Number Date

of

Issue

Number Date

of

issue

For Imported Items

Details of

Licenses -

Imported

Items

Minimum 1 rows entry required. Number of Rows To Add:

S.

No.

Item

No. Import License Form

10

Country

of

Origin

COPP Form 20B/21B Form 41 No

Conviction

Proprietary

Drug

Certificate

New

molecule/Dr

ug

Certificate

Number Valid

Upto

Page

No.

Valid

Upto

Numbe

r

Date of

Issue

Valid

Upto

Page

No.

Number Valid

Upto

Page

No.

Date

of

Issue

Page

No.

Number Date

of

Issue

Number Date

of

issue

28

ANNEXURE B

MANUFACTURING & MARKETING CERTIFICATE

This is to certify that M/s._________________________ are holding valid manufacturing licenses No.______________________________ date____ of the State and they are manufacturing the following products since the last three years. It is further certified that the following products are also being marketed for the last three years.

The products are as follows:-

S.No. Item No. Item Name Pharmacopoeia

Strength

Strength

1

2

3

Note :

1. This certificate is to be signed by the Drug Controller of State. Certificate issued by Inspector of Drugs/Drug Inspector will not be accepted unless their authorization by the State Drug Controller to this effect is supported by documentary proof.

2. Firm should have three completed years experience of manufacturing and marketing as on date

of opening of the tender.

Dated:

Signature and seal of

Drug Controller of the State

29

Annexure 'C'

TO BE FILLED IN BY BIDDER AND RETURNED WITH THE TENDER

To,

Dy. Medical Commissioner (R.C.),

Room No. 312 & 314, III Floor,

Hqrs. Office, ESI Corporation, Panchdeep Bhawan

C.I.G. Road, New Delhi – 110 002

Dear Sir / Madam,

We return herewith your e-Tender Enquiry for Rate Contract no 142 dated

22.12.2017 with our quotation against respective items. We have carefully perused the

Terms and Conditions of the Rate Contract and accept the same.

For and on behalf of the firm

(Firms Name & Address)

(Signature of Authorized signatory)

WITNESS:

Signed in my presence:

Name:

Designation:

Seal:

Notary Public/Gazetted Officer

( Name & Complete Address)

30

Annexure - 'D'

PRODUCTION CERTIFICATE

Indicate details of production of the items quoted, for the last three preceding years

duly certified by the concerned State Drug Controller.

S. No. Item No. Item Name &

Description

Date of issue of

Mfg. License for

the product

Date of marketing

the 1st batch

1. 2. 3. 4. 5.

6. ACTUAL PRODUCTION DETAILS

Year – 2014-15 Year 2015-16 Year 2016-17 Remarks

Batch No. Batch size Batch No. Batch

size

Batch

No.

Batch size

Signature of the

Manufacturer

Signature of the State

Drug Controller along with address &

Seal.

Note: Firm will have to produce documentary evidence in respect of production as and when

asked for.

31

Annexure -E

Proforma to be filled in by the Tenderer.

I GENERAL INFORMATION

a) Name of the firm:

b) (Information must be correct): -

Address for correspondence:

Telephone No.:

Working Fax No (Must be provided).:

Mobile No.

E-mail address for all Correspondences

including placing of Supply order :

c) Whether the firm is Indian / Multi-national.

d) Whether small/medium/ Large scale

company.

e) Whether Firm registered as Micro & Small

Enterprises Firm under the Ministry of Micro

Small and Medium enterprises

f) Person responsible for conduct of business

g) Particulars of Licenses held under Drugs &

Cosmetics Act & the details. (If the license is

under renewal, certificate from the Drug

Controller that the license is under renewal

and deemed to be enforced should be

enclosed.

h) Procurement agency with which registered

and the agencies to whom drugs quoted

supplied during last one year.

i) i.) Has the firm ever been convicted, if yes

give details.

ii.) Any case pending in Court with details.

j) Has the firm ever been black listed/debarred

by any procurement agency. If yes, details

thereof.

k) Has the firm ever been debarred/black listed

for supply of drug/drugs by ESI Corporation:

if yes, give details

32

II TECHNICAL

a) Equipments for material handling, manufacturing of drugs and quality control of drugs.

b) Specialised testing facilities such as Microbiological testing and biological testing;

c) Details of Technical Staff: i.) Manufacturing Staff: ii.) Quality Control Staff:

d) Has the firm carried out stability study for drugs quoted: e) Is the firm basic manufacturer of the drug quoted, if yes, details: f) Drugs declared sub-standard/recalled during the last three years. Give details

with reasons and the remedial action taken: III FINANCIAL

a) Annual Turn-over for formulations during the last three years (year wise) (Must be filled)

i. 2014-15 : _________ ii. 2015-16 : _________ iii. 2016-17 : _________

b) Name & Address of the Bankers to the firm ______________________ _________________________________________________________

_________________________________________________________

c) GSTIN No. NOTE: The bidder will submit an undertaking of GST ACT compliance on

a non-judicial stamp paper of Rs. 50/-. ESIC will not hold any responsibility including impact on price due to non-compliance of GST Act.

DECLARATION

I__________________________________ proprietor/partner/director of M/s.

__________________________________ hereby declare that the information given in this

form is true and correct to the best of my knowledge and belief.

Signature:

Name:

Designation:

Seal:

WARNING: If information furnished in this form is subsequently found to be incorrect the

tenderer will be black listed.

33

Annexure(G)

UNDERTAKING

We hereby undertake that rates offered by us in the DG-ESIC Rate Contracts are

within the price ceiling fixed by National Pharmaceuticals Pricing Authority (NPPA),

Ministry of Chemical & Fertilizers. We further undertake that in case there is any down-

ward revision by the NPPA, same will be passed on to the ESI Corporation from the

effective date during the currency of the contract and in case of failure to do so we are

liable to be debarred from future ESIC Tender Enquiry for a further period of two years

alongwith forfeiting the earnest money.

For and behalf of the firm

(Firm Name & Address)

34

Annexure - P

PRICE BID

S.

No

Item

No.

Item Name

& Description

Unit Net Rates /

Unit **

offered

(in figures)

Net Rates

offered/

Unit

(in words )

Applicable

GST

Brand

Name

Is Price

Notified by

NPPA, if yes,

Order No. &

Ceiling Price

*Retail

Sale

Price

1. 2. 3. 4. 7. 8. 9. 10. 11. 12.

1. AA AAA 1 tab 2.6666

Upto Four

decimal

places

Rs. Two and

paise Six Six

Six Six only

1

* “Retail Sale Price” means the retail price displayed by the manufacturer under the provisions of the Drug (Prices Control) Order, 1995.

For Column No 9- Please enter 0 or 1

0 for NO GST

1 for GST as applicable

NOTE: ** Unit Rates for all Tab / cap shall be quoted for 1 tab/cap

Unit Rates for all bottles / oint/ inj/ vial shall be quoted for 1 bottle/ oint/ inj./vial etc.

35

Annexure T

Guarantee bond on a affidavit of Rs. 50/- (Rupees Fifty only) duly signed by the

Notary

“The pharmaceutical firm hereby declare that the drugs/items sold to the ESIC under this contract

shall be of best quality and workmanship and shall be strictly in accordance with the specifications

and particulars contained/mentioned in the description clauses hereof and the pharmaceutical

firm/bidder hereby guarantees that the said drugs/items would continue to conforms to their

description/ specification and the provisions of law as stated in the contract and that

notwithstanding the fact that the purchaser (inspector) may have inspected and/or approved the

said drugs/items. If the same be discovered not to conform to the description and quality

aforesaid or have deteriorated, the decision of the ESIC in that behalf will be final and conclusive.

ESIC will be entitled to reject said drugs/items or such portion thereof as may be discovered not to

conform to the said description and quality in the manner as prescribed. Such rejection of the

drugs/items will be at the seller's risk and all the provisions herein contained relating to rejection

of drugs/items etc. or such portion thereof if is rejected by the purchaser. Nothing herein

contained shall prejudice any other right of ESIC in that behalf under this contract or otherwise”.

Signature:

Name:

Designation:

Seal

36

Annexure EMD

Earnest Money Deposit Criteria

SNo. Item No.

Name of the Drugs Drugwise EMD (in Rs.) as per the Drug Schedule

Sum total of EMD submitted in Rs.

Signature:

Name:

Designation:

Seal

37

Annexure TO

Turnover Criteria as per clause 16 of the tender

SNo. Item No.

Name of the Drugs Drugwise Turnover (in Rs.) as per the Drug Schedule

Sum total of Turnover for drugs quoted(in Rs.)

Total Annual Turnover of the firm for drugs and their formulations for the year 2014-15

Annual Turnover of the firm for the year 2014-15 from Trade/Market other than Govt. Institutions





Signature:

Name:

Designation:

Seal

38

**CHECK LIST OF THE DOCUMENTS ONLINE:

1. Earnest Money Deposit as calculated in the form of Demand Draft. MSE firms are exempted

from submitting EMD subject to submission of valid MSE Certificate from appropriate

authority (as per S.No. 23 of Check List).

2. Forwarding letter of the pharmaceutical firm

3. List of items quoted as per Annexure ‘A’ (without rates).

4. Three years’ Manufacturing & Marketing Experience certificate duly signed by the State Drug

Controller in prescribed format i.e. Annexure-B (should not have been issued more than a

year ago).

5. Certificate of acceptance of Terms and Conditions in Annexure ‘C’.

6. Production certificate for the last three preceding years in respect of drugs quoted as per

Annexure ‘D’. For Imported items- i) Form 10 , ii) form 41.

7. Information as per prescribed proforma(Annexure ‘E’).

8. Manufacturing and marketing details of the product quoted as per the prescribed format

(Annexure ‘F’).

9. Undertaking as per Annexure-‘G’.

10. Audited financial statement (Balance Sheet and Profit & Loss Account Statement) in respect

of annual turnover for formulations. (Only relevant documents are to be uploaded).

Fifty Percent or more of the annual turnover shall be from the trading of the drugs in open

market i.e exclusive of supply to ESI/ Government Departments. A certificate from the

Chartered Accountant with reference to sale in the open market should be uploaded.

11.

a. Attested photocopy of DGQA Registration Certificate.(As applicable)

b. Attested photocopy of valid WHO-GMP Certificate.(As applicable)

c. Attested photocopy of valid GMP Certificate as per the revised Schedule ‘M’ of the Drugs

& Cosmetics Rules. (As applicable )

12. Attested photocopy of valid GLP Certificate as per schedule ‘L1’ of the Drugs & Cosmetics

Rules for the quoted drugs. However the bidders quoting for dressing material such as gauze &

gauze & bandage etc. are exempted from submitting GLP Certificate whereas the provisions

prescribed under Drugs & Cosmetics Act, 1940 & Rules thereunder as amended from time to

time are applicable.

13. Attested photocopy of Drug Manufacturing License with the list of products approved.

14. Certificate of approval of Drug Controller General of India for new drugs (if applicable).

15. Certificate of sole manufacturer/ Proprietary of product from State Drugs Controller.

16. Valid import license – Form 10 & Form 41 (if applicable )

17. Non-Conviction Certificate for last three continuous years. Non-Conviction Certificate must

have been issued on or after 30.09.2017 from the Drug Controller of the concerned State.

18. Copy of the recent GST Certificate along with affidavit The bidder will submit an

undertaking of GST ACT compliance on a non-judicial stamp paper of Rs. 50/-. ESIC

39

will not hold any responsibility including impact on price due to non-compliance of GST

Act.

19. Attested photocopy of valid ISI license /Certificate (in case of items where “ISI Mark” is

asked for ).

20.

i. Affidavit of Guarantee Bond – as per clause 14)N of Terms & Conditions. (Annexure T)

ii. Affidavit – as per clause 14) T of Terms and Conditions.

21. Original Label of all the products quoted.

22. Company/Authorized Signatory to submit Employer Code No. & copy of last three

contributions towards ESI in case factory is covered under ESI Act.

OR

Company/Authorized Signatory to submit an Affidavit giving address of Manufacturing unit

with a declaration that this factory / manufacturing unit is outside the implemented area /

notified area by ESI Corporation.

OR

Company / Authorized Signatory to submit a certificate from the Regional Director that the

factory is not coverable under ESI Act, in case the factory is within the covered / notified area.

23. Certificate of Registration of the company as Micro and Small enterprises under the Ministry

of Micro Small and Medium enterprises from appropriate authority. (if applicable )

24. Letter of authorization to sign and submit the tender along with specimen signature of the

authorized signatory.

25. Annexure ‘P’ & Detail of licenses are to be filled. Annexure EMD & TO are to be uploaded.

26. Copy of any other document as required.

Note:

It is the sole responsibility of the bidder to submit the tender both Online & Manually as

listed. All documents as listed above should be clear & legible, duly attested / notarized,

properly indexed & serially page numbered. All documents should be duly signed digitally

for online submission and manually for hard copy by the authorized signatory. Copies to be

uploaded and submitted online should be in proper resolution.

The above said instructions should be followed strictly, failing which the tender will be

summarily rejected.

The bidder who submits false, forged or fabricated documents or conceals facts with intent

to win over the tender, EMD of such bidder will be forfeited and pharmaceutical firm will

be liable for blacklisting in addition to legal action as deemed fit.

ESIC...C.I.G. ROAD, NEW DELHI ... Processing Fee in the form of Demand Drafts to the Service...

Documents

Transcript of ESIC...C.I.G. ROAD, NEW DELHI ... Processing Fee in the form of Demand Drafts to the Service...